Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

“This event brings together industry executives, clinical thought leaders and investment professionals to discuss therapeutic areas of need and expectations for the market environment of the future”

"This event brings together industry executives, clinical thought leaders and investment professionals to discuss therapeutic areas of need and expectations for the market environment of the future," said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO. "Therapeutic sessions will highlight disease areas with key catalysts representing new therapies and cutting edge investment opportunities."

The BIO CEO & Investor Conference's therapeutic workshops will focus on topics addressing the latest developments in therapies for a wide range of diseases. This year's therapeutic workshop topics include:

Oncology: Lung Cancer - Clearing the Airways on New Treatments
Monday, February 14, 9:00am-9:55am

• Brian Schwarz, Chief Medical Officer, ArQule, Inc.

Urology: Prostate Cancer-Shedding Light in Dark Places
Monday, February 14, 2:00pm-2:55pm

• David Hung, MD, President & Chief Executive Officer, Medivation, Inc.
• Scott Cormack, President & Chief Executive Officer, OncoGenex Pharmaceuticals, Inc.
• David Nanus M.D., Co-Chief of the Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital

Rheumatoid Arthritis: the Real Joint Problem
Tuesday, February 15, 9:00am-9:55am

• James M. Gower, Chairman of the Board & Chief Executive Officer, Rigel Pharmaceuticals, Inc.
• Thomas J. Schall, PhD, President & CEO, ChemoCentryx, Inc.
• Simos Simeonidis, PhD, Managing Director, Rodman & Renshaw, LLC (moderator)

Trial and Error: Breaking Down Clinical Trial Success Rates
Tuesday, February 15, 12:00pm-12:55pm

• Ted Buckley, PhD, Chief Economist, Bloomberg (moderator)
• Michael Hay, Senior Biotechnology Analyst, Sagient Research Systems
• David Thomas, Director, Industry Research & Analysis, Biotechnology Industry Organization (BIO)

Psychiatry: Major Depressive Disorder - A Lifeline for the Pipeline
Tuesday, February 15, 3:00pm-3:55pm

• Elemer Piros, PhD, Managing Director & Senior Biotechnology Analyst, Rodman & Renshaw, LLC (moderator)
• Barry Brand, Chief Executive Officer & Director, CeNeRx Biopharma, Inc.
• Geoffrey C. Dunbar, MD, Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer, Targacept, Inc.
• Alexander Glassman, M.D., Chief of Clinical Psychopharmacology, New York State Psychiatric Institute

(Additional panelists to be confirmed.)